Exini Diagnostics : heart-product fast growing on the Japanese market - hits 300 installed units

Lund September 8, 2014

EXINI's heart-product fast growing on the Japanese market - hits 300 installed units Market penetration for the heart-product EXINI heart (cardioREPO in Japan) exceeds expectations. FUJIFILM RI Pharma Co. Ltd carries the exclusive rights for EXINI heart in Japan, and has over the past months installed 300 units of the software system cardioREPO in clinics throughout Japan.

"Japanese doctors show great interest in cardioREPO as we introduce it to them. The unique features and advanced functions have been developed over the past two years and stems from extensive input from Japanese physicians. The launch of cardioREPO in Japan provide both doctors and patients the possibility to benefit from this hard work", explains Takehiro Ishikawa, Product Manager, FUJIFILM RI Pharma.

"The collaboration with FUJIFILM RI Pharma is working well and the rate of installations continues to impress us", comments Magnus Aurell, CEO EXINI Diagnostics AB

About EXINI heart (cardioREPO) - cardiology

The product cardioREPO is an advanced customization of the diagnostic software system EXINI heart developed for the Japanese market, providing clinics and specialists with advanced information crucial in managing patients suffering from suspected or known ischemic heart conditions (e.g. Heart attacks or Angina).

For more information, please contact:

Magnus Aurell, CEO

Phone: [phone]

E-mail: [e-mail]

About EXINI Diagnostics AB (publ)

EXINI Diagnostics AB (publ) offers advanced solutions for medical decision support to hospitals worldwide. The system is based on
advanced image analysis by artificial intelligence and can make its own interpretation of medical images and provide diagnostic suggestions. In this way the system is used as a decision support for the diagnosing doctor. EXINI is working with products for the diagnosis of some of the most frequent endemic diseases such as cancer, coronary heart disease, dementia and Parkinson's disease. The company was founded in 1999 by Professor Lars Edenbrandt. EXINI is listed on the stock market NASDAQ OMX First North and has about 600 shareholders. Principal owner is Bo Håkansson. Thenberg & Kinde Fondkommission AB acts as Certified Advise

EXINI Diagnostics AB, Ideon Science Park, Scheelevägen 27, SE-223 70 Lund, Sweden
Phone: [phone], Fax: [phone], [e-mail], www.exini.com, VAT-no: SE556576199501